A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Unresectable Melanoma · Metastatic Melanoma · Ocular Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
SCRI Oncology Partners- Denver, Denver, Colorado, United States
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Greenslopes Private Hospital, Greenslopes, Queensland, Australia
Hollywood Private Hospital Ramsay, Nedlands, Western Australia, Australia
Study leads
Iovance Biotherapeutics Study Team
Study Director
Iovance Biotherapeutics